



Mo-99: Our promise to the global health care community

Harrie Buurlage

Chief Commercial Officer, Isotopes
General Manager Europe

SHINE

October 2023

— Our promise to the global health care community

1. Low LEU use (recycling loop), low HRA waste, intrinsically safe
2. Decreases dependency on ageing, capacity constrained high flux research reactors
3. Decreased cost of production compared to current process
– CapEx and OpEx
4. A future with Mo-99 (and other uranium fission based medical isotopes) produced all on one site (full internal integration)
5. Flexible and easy to access neutron sources for R&D and key neutron activation medical isotopes

Subcritical Hybrid Intense Neutron Emitter



— The path to eliminating barriers

Risk-reward ratio as a constantly moving target

- ✓ Assure a meaningful level playing field between government subsidized producers & private organizations
- ✓ National governments should withdraw from areas where private solutions prevent (projected) market failures

Maintaining credibility as a break-through innovator

- ✓ Appreciate and support first-of-its-kind technologies as “by definition” they have no credible reference projects
- ✓ Implement a meaningful FCR as the time & schedule risks of the “unknown-unknowns” force first-in-kind solutions to be much better than FCR